On Monday, Shares of Apple Inc. (NASDAQ:AAPL), gained 0.20% to $130.54. The company exchanged hands with 32,116,927 shares as compared to its average daily volume of 48,763,800 shares. The company has the market capitalization of 752.02B.
The stock volatility for the week is 1.50%, while for the month remained 1.63%. The company holds consensus target price of $148.75.
If we consider EPS growth of the company, then the company indicated the following observations:
The company showed 8.09 diluted EPS growth for trailing twelve months. However, YTD EPS growth remained 13.60% and Annual EPS growth for the past 5 years is considered as 37.80%.
The mean recommendation of analysts for this stock is 2.00. (where 1=Buy, 5=Sale).
Apple Inc. designs, manufactures, and markets mobile communication and media devices, personal computers, watches, and portable digital music players worldwide. The company also sells related software, services, accessories, networking solutions, and third-party digital content and applications.
Shares of ImmunoGen, Inc. (NASDAQ:IMGN), skyrocketed 71.94% to $15.44, during its last trading session, hitting its highest level. The company exchanged hands with 24,406,395 shares as compared to its average daily volume of 1,869,380 shares. The company has the market capitalization of 1.33B.
ImmunoGen, declared the presentation at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting of the first clinical findings in a disease-specific patient population with the Company’s unique, FRα-targeting ADC, mirvetuximab soravtansine (abstract #5518).
The findings stated are from an ongoing Phase 1 trial. Once the recommended Phase 2 dose (RP2D) of mirvetuximab soravtansine was established during dose finding (abstract #5558), an expansion cohort was opened to assess the safety and activity of this ADC specifically in the treatment of patients with FRα-positive platinum-resistant ovarian cancer. About 80% of the patients screened have met the criteria for having FRα-positive disease.
Twenty-two patients were comprised of in the analysis stated recently – two from the dose-escalation phase of the trial and the twenty enrolled in the expansion cohort at the time of data cutoff for presentation (4/30/15). All had FRα-positive platinum-resistant ovarian cancer and had received mirvetuximab soravtansine at the RP2D (6.0 mg/kg, given every three weeks). All had formerly received taxane in addition to platinum therapy. Thirteen were still on study at the time of data cutoff.
The majority of adverse events stated were low grade (grade 1 or 2), with diarrhea, blurred vision, nausea, vomiting, fatigue, and abdominal pain the most common treatment-emergent events stated (>20% of patients).
Seventeen of the 22 patients were comprised of in the efficacy analysis; the other five patients were still on study and had not yet reached their first assessment.
- Nine of these 17 patients had an objective response (8 partial responses, 1 complete response) to treatment, for an ORR of 53%.
- The responses in six of these nine patients were ongoing at the time of data cutoff, with five of these six patients on treatment for more than 15 weeks.
ImmunoGen, Inc., a biotechnology company, develops targeted anticancer therapeutics. It develops its products using its antibody-drug conjugates technology. The company offers Kadcyla, an antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer.
Gold prices fell Monday, after the dollar resumed its rally and outweighed support from lackluster U.S. economic data.
The most actively traded contract, for August delivery, fell $1.10, or 0.1%, to settle at $1,188.70 a troy ounce on the Comex division of the New York Mercantile Exchange.
“With the dollar strength ongoing, there’s pressure on gold,” said Dave Meger, director of metals trading with High Ridge Futures in Chicago.
Among Gold Stocks, Shares of Newmont Mining Corporation (NYSE:NEM), lost -0.26% to $10.72. The company exchanged hands with 3,644,824 shares as compared to its average daily volume of 6,808,270 shares. The company has the market capitalization of 13.58B.
The stock opened its last trade with market price of $27.35.
Newmont Mining Corporation operates in the mining industry. It primarily acquires, develops, explores for, and produces gold, copper, and silver deposits. The company’s operations and/or assets are located in the United States, Australia, Peru, Indonesia, Ghana, and New Zealand.
Finally, IMRIS, Inc. (NASDAQ:IMRS), ended its last trade with -28.74% decline, and closed at $0.03, hitting its lowest level.
IMRIS, declared that the Company received a letter May 26, 2015 from the NASDAQ Stock Market LLC, stating that in accordance with Listing Rules 5101, 5110(b), and IM-5101-1, the Staff has determined that the Company’s securities will be delisted from The NASDAQ Stock Market. Accordingly, trading of the Company’s Common Shares will be suspended at the opening of business on June 4, 2015, and a Form 25-NSE will be filed with the Securities and Exchange Commissions (the SEC), which will remove the Company’s securities from listing and registration on The Nasdaq Stock Market. The Nasdaq staff determination was based on the following factors: the associated public interest concerns raised by the Company’s press release dated May 26, 2015 in which the Company declared it has filed for protection under Chapter 11 of the U.S. Bankruptcy Code; concerns regarding the residual equity interest of the existing listed securities holders; and concerns about the Company’s ability to sustain compliance with all requirements for continued listing on The Nasdaq Stock Market.
IMRIS Inc. designs, manufactures, and sells image-guided therapy solutions worldwide. The company offers VISIUS Surgical Theatres, a surgical environment that provides intraoperative vision to clinicians to assist in decision-making and enhance precision in treatment.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
